There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Open Label Optimization Study
NCT05819021
Recruiting
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will receive 10 treatments per day for 5 days (M-F) of SAINT®
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: LA TMS, Los Angeles, California
Conditions: Major Depressive Disorder
Register for Updates
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
NCT04970992
Recruiting
The primary goal of this Phase 1 study is to characterize the safety and tolerability of DZ-002 and establish the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of DZ-002 administered on a weekly schedule in patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of DZ-002 will also be assessed.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Solid Tumor, Lymphoma
Register for Updates
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
NCT05175352
Recruiting
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: GastroIntestinal Biosciences, Los Angeles, California
Conditions: Eosinophilic Esophagitis
Register for Updates
Epilepsy Learning Healthcare System (ELHS)
NCT06265103
Recruiting
The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy. The ELHS is designed as a model of value-based chronic care for epilepsy as envisioned by the National Academies of Medicine Committee in their landmark reports "The Learning Health System" and "Epilepsy Across the Spectrum: Promoting Health and Understanding". The ELHS network is a collaboration among clinicians, patients and researchers that promotes the use o... Read More
Gender:
All
Ages:
All
Trial Updated:
02/15/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
Register for Updates
NEO100 and High-Grade Meningioma
NCT05023018
Recruiting
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times d... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
02/14/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Residual, Progressive or Recurrent Grade II or III Meningioma
Register for Updates
Norris ORIEN Total Cancer Care
NCT02970045
Recruiting
This research trial collects biological samples and clinical information to create a repository of data from patients with cancer or a predisposition for cancer. Combining genetic information from biological samples and clinical data may lead to more knowledge about why certain cancers respond to treatment and help create more personalized medicine.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Cancer Risk, Malignant Neoplasm
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Keck School of Medicine, Los Angeles, California
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
NCT05600777
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: California Allergy & Asthma Medical Group Inc., Los Angeles, California +1 locations
Conditions: Refractory Chronic Cough
Register for Updates
Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS
NCT05996575
Recruiting
The goal of the proposed observational, multi-site study is to use fNIRS neurophysiological data recorded during a battery of tasks to detect MCI within a cohort consisting of patients and age-matched healthy controls. Furthermore, the investigators aim to explore whether they can measure the severity of MCI symptoms in the patient population. If successful, this approach enables clinicians to track the disease at its source-the brain; possibly allowing for earlier detection of MCI and its progr... Read More
Gender:
All
Ages:
Between 55 years and 85 years
Trial Updated:
02/14/2024
Locations: Kernel, Los Angeles, California
Conditions: Mild Cognitive Impairment
Register for Updates
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358
Recruiting
COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: UCLA, Los Angeles, California
Conditions: Acute Myocardial Infarction, Coronary Artery Disease
Register for Updates
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
NCT02717156
Recruiting
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. Cohort B, phase II 3rd lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: LAC+USC Medical Center, Los Angeles, California +1 locations
Conditions: Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
Register for Updates
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Keck Medicine of University of Southern California, Los Angeles, California
Conditions: Non Small Cell Lung Cancer
Register for Updates